KR20210021982A - 췌장암 치료용 화합물 - Google Patents

췌장암 치료용 화합물 Download PDF

Info

Publication number
KR20210021982A
KR20210021982A KR1020207035812A KR20207035812A KR20210021982A KR 20210021982 A KR20210021982 A KR 20210021982A KR 1020207035812 A KR1020207035812 A KR 1020207035812A KR 20207035812 A KR20207035812 A KR 20207035812A KR 20210021982 A KR20210021982 A KR 20210021982A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
another embodiment
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207035812A
Other languages
English (en)
Korean (ko)
Inventor
웨이 리
두앤 디 밀러
수바쉬 차우한
비베크 쿠마르 카쉬야프
왕 큉후이
Original Assignee
유니버시티 오브 테네시 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 테네시 리서치 파운데이션 filed Critical 유니버시티 오브 테네시 리서치 파운데이션
Publication of KR20210021982A publication Critical patent/KR20210021982A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020207035812A 2018-05-15 2019-05-15 췌장암 치료용 화합물 Withdrawn KR20210021982A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
US62/671,833 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
KR20210021982A true KR20210021982A (ko) 2021-03-02

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035812A Withdrawn KR20210021982A (ko) 2018-05-15 2019-05-15 췌장암 치료용 화합물

Country Status (9)

Country Link
US (1) US20190374512A1 (https=)
EP (1) EP3793548A4 (https=)
JP (1) JP2021523915A (https=)
KR (1) KR20210021982A (https=)
CN (1) CN112437664A (https=)
AU (1) AU2019270091A1 (https=)
CA (1) CA3099922A1 (https=)
MX (1) MX2020012292A (https=)
WO (1) WO2019222392A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230413A1 (es) * 2020-04-03 2023-03-07 Veru Inc Metodos de tratamiento del coronavirus
CA3215936A1 (en) * 2021-04-05 2022-10-13 Veru Inc. Methods of treating inflammation
CN119212696A (zh) * 2022-04-28 2024-12-27 维鲁公司 [2-(1h-吲哚-3-基)-1h-咪唑-4-基](3,4,5-三甲氧基)甲酮和其盐的多晶型物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
JP5879273B2 (ja) * 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
JP5997156B2 (ja) * 2010-08-24 2016-09-28 ジーティーエックス・インコーポレイテッド 癌の治療のための化合物
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
EP3793548A4 (en) 2022-03-09
AU2019270091A1 (en) 2020-12-24
WO2019222392A1 (en) 2019-11-21
EP3793548A1 (en) 2021-03-24
CN112437664A (zh) 2021-03-02
JP2021523915A (ja) 2021-09-09
CA3099922A1 (en) 2019-11-21
US20190374512A1 (en) 2019-12-12
MX2020012292A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
KR102246652B1 (ko) 암 치료용 화합물
JP7342183B2 (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
JP7114745B2 (ja) トリプルネガティブ乳癌および卵巣癌の治療のための化合物
JP5879273B2 (ja) 癌を処置するための化合物
KR102452370B1 (ko) 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법
RU2762111C1 (ru) Соединения для лечения рака
KR102634575B1 (ko) 지방세포의 처리
US11084811B2 (en) Compounds for treatment of cancer
US12152036B2 (en) Substituted pyrrolo[1,2-α]quinoxalin-4(5H)-ones as CX3CR1 antagonists
KR20210021982A (ko) 췌장암 치료용 화합물
KR20190018486A (ko) 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법
HK40043322A (en) Compounds for treatment of pancreatic cancer
US20150065486A1 (en) Methods for treating polycystic kidney disease
RU2776897C2 (ru) Соединения для лечения трижды негативного рака молочной железы и рака яичника
HK40043706A (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
JP2007504164A (ja) ＰＰＡＲ−γ経路およびＨＥＲ−キナーゼ軸の調節に基づく癌および他の生理学的状態の処置のための組成物および方法
US20100022600A1 (en) Methods and compositions for treating central nervous system tumors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201211

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination